Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 23 min ago
Peer-reviewedLicence not statedActa Pharmacologica Sinica

Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance

  • Yi Chen1,2
  • Qiu-pei Liu1
  • Si-jie Yang3
  • Jian Ding1
  • Xiao-yun Lu3
  • Hua Xie1,4
4 affiliations
  1. 1Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203 China
  2. 2Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200433 China
  3. 3School of Pharmacy, Jinan University, Guangzhou, 510632 China
  4. 4Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400 China
Read full textDOICite

Related

  1. The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges
    Tancredi Didier Bazan Russo, Valerio Gristina, Francesco Pepe +13
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  2. Challenges and opportunities for strengthening South American responses to insecticide resistance in disease vectors: Lessons from the WINSA workshop in Bogotá, Colombia
    Ademir J Martins, Martha Ahumada, Tashanna S Bowman +18
    PLOS Neglected Tropical DiseasesPeer-reviewedCC0Full textZoology & animal behaviourEpidemiology & public healthPLOSEurope PMCEurope PMCPMC
  3. Dual plasmepsin IX and X inhibitors are refractory to development of resistance
    Paola Favuzza, Madeline G. Dans, Wenyin Su +15
    PLOS PathogensPeer-reviewedCC BY 4.0Full text2 citedGenetics & genomicsMicrobiologyPLOS
  4. Evolving skin cancer therapeutics: molecular and genetic drivers, immunotherapy challenges, and advances in nanogel-based nanomedicine
    Sabah Aafreen, Sayed Abdur Rehman, Tahmeed Parvez Barbhuiya +5
    NanomedicinePeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  5. Challenges and opportunities in emotion dynamics research: an interdisciplinary perspective
    Nikolaos Vasileiadis, Daouia Larabi, Peter de Jonge +1
    PsyArXivPreprintAll rights reservedFull textPsychiatry & mental healthOSF

Cite

BibTeXRIS
BibTeX
@article{chen2026opportunities,
  title = {{Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance}},
  author = {Yi Chen and Qiu-pei Liu and Si-jie Yang and Jian Ding and Xiao-yun Lu and Hua Xie},
  journal = {Acta Pharmacologica Sinica},
  year = {2026},
  month = jul,
  doi = {10.1038/s41401-026-01855-0},
  url = {https://doi.org/10.1038/s41401-026-01855-0},
}
RIS
TY  - JOUR
TI  - Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
AU  - Yi Chen
AU  - Qiu-pei Liu
AU  - Si-jie Yang
AU  - Jian Ding
AU  - Xiao-yun Lu
AU  - Hua Xie
PY  - 2026
DA  - 2026/07/08
JO  - Acta Pharmacologica Sinica
DO  - 10.1038/s41401-026-01855-0
UR  - https://doi.org/10.1038/s41401-026-01855-0
SN  - 1671-4083
SN  - 1745-7254
ER  -